VCP
ITCI

Verus Capital Partners’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Verus Capital Partners’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-3,000
Closed -$103K – 1614
2019
Q4 		$103K Buy
+3,000
New +$36K 0.03% 371

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Verus Capital Partners's ITCI Position: Q1 2020 in Review

Verus Capital Partners sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2020, closing a stake of 3,000 shares — an estimated $103K sold.

Verus Capital Partners first reported a position in ITCI in Q4 2019 and held it in 1 quarter. The position peaked at $103K in Q4 2019. 139 funds tracked by Wall St. Rank hold ITCI as of Q1 2020.

  • Verus Capital Partners reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2020 after selling out during the quarter.
  • Verus Capital Partners sold 3,000 Intra-Cellular Therapies Inc. shares in Q1 2020, an estimated $103K.
  • Verus Capital Partners first reported a position in Intra-Cellular Therapies Inc. in Q4 2019 and held it in 1 quarter.
  • Verus Capital Partners's Intra-Cellular Therapies Inc. position peaked at $103K in Q4 2019.
  • 139 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2020.

Based on Verus Capital Partners's 13F filing for Q1 2020, filed 26 May 2020.